Document Detail


Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to preeclampsia.
MedLine Citation:
PMID:  16996762     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the relationship between maternal serum and amniotic fluid levels of human Placental Growth Hormone (hPGH) with the fetal intrauterine growth retardation (IUGR) related to preeclampsia. DESIGN: We analyzed samples in pairs of serum and amniotic fluid retrospectively from 25 women, who manifested preeclampsia and IUGR in the late second or the third trimester of gestation. The samples were obtained at 16-22 weeks' gestation during amniocentesis for fetal karyotyping. At this time, there was no clinical or sonographic evidence of preeclampsia or IUGR, respectively. Sixty-two serum samples were used as controls which were obtained at 16-22 weeks' gestation from women with singleton, uncomplicated pregnancies, with normal outcome, and appropriate for gestational age neonatal birth weight. Forty-seven amniotic fluid samples were also used as controls which were obtained at 16-22 weeks' gestation from the women that were included in the control group who underwent an amniocentesis. hPGH levels were measured by a solid phase immunoradiometric assay. RESULTS: The mean hPGH values in the serum and the amniotic fluid of the IUGR related to preeclampsia affected pregnancies were significantly higher (P<0.05) than those of the normal pregnancies at 16-22 weeks' gestation: mean+/-SD in the serum was 13.16+/-10.52 ng/ml vs. 4.39+/-2.23 ng/ml; mean+/-SD in the amniotic fluid 2.49+/-1.6 ng/ml vs. 0.82+/-0.67 ng/ml. CONCLUSION: hPGH levels in maternal serum and amniotic fluid were found to be higher at 16-22 weeks' gestation in pregnancies that will be complicated subsequently by IUGR related to preeclampsia. Our findings suggest that the evaluation of the changes of hPGH levels at midtrimester should be further investigated for the possibility to provide a potential predictive index of IUGR and preeclampsia.
Authors:
E Papadopoulou; S Sifakis; E Giahnakis; Y Fragouli; N Karkavitsas; E Koumantakis; M Kalmanti
Publication Detail:
Type:  Journal Article     Date:  2006-09-25
Journal Detail:
Title:  Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society     Volume:  16     ISSN:  1096-6374     ISO Abbreviation:  Growth Horm. IGF Res.     Publication Date:    2006 Oct-Dec
Date Detail:
Created Date:  2006-11-27     Completed Date:  2007-01-31     Revised Date:  2010-09-21    
Medline Journal Info:
Nlm Unique ID:  9814320     Medline TA:  Growth Horm IGF Res     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  290-6     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, University of Crete, 71201 Heraklion, Greece. bm-pjhkka@otenet.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amniocentesis
Amniotic Fluid / metabolism
Birth Weight
Case-Control Studies
Female
Fetal Development / physiology
Fetal Growth Retardation / blood*,  etiology,  metabolism*
Gestational Age
Growth Hormone / blood*,  metabolism*
Humans
Infant, Newborn
Placental Hormones / blood*,  metabolism*
Pre-Eclampsia / blood*,  etiology,  metabolism*
Pregnancy
Pregnancy Trimester, Second
Pregnancy Trimester, Third
Retrospective Studies
Chemical
Reg. No./Substance:
0/GH2 protein, human; 0/Placental Hormones; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pyrolysis mechanism of carbon matrix precursor cyclohexane--the formation of condensed-ring aromatic...
Next Document:  Metabolic engineering of the heterologous production of clorobiocin derivatives and elloramycin in S...